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ABSTRACT
SYNTHESIS AND CHARACTERIZATION OF
TARGETED BAR ENCAPSULATED POLY LACTIC-CO-GLYCOLIC ACID
NANOPARTICLES
TO INHIBIT PORPHYROMONAS GINGIVALIS BIOFILM FORMATION
Ranjith Radha Krishnan
April 13, 2017
Periodontal disease is one of the most prevalent infectious diseases worldwide. Between
30-50% of the global adult population suffers from periodontal disease. Some form of
periodontitis is present in 46% of American adults, corresponding to annual expenditures
in excess of 14 billion dollars for treatment and prevention. Current treatments for
periodontal diseases involve mechanical removal of plaque, correction of risk factors,
gingival surgery and/or antibiotic therapy. To our knowledge there is no effective
therapeutic approach that aims to limit pathogen colonization of the oral biofilm or recolonization after treatment. Interaction of the pathogen Porphyromonas gingivalis with
oral streptococci is critical in the pathogenesis of periodontal diseases. Our previous studies
identified a peptide (BAR) that potently inhibited this interaction and reduced P. gingivalis
virulence in vivo. However, BAR required higher concentrations and prolonged exposure
in limiting P. gingivalis in a pre-established biofilm. This study is aimed at developing
targeted BAR encapsulated poly(lactic-co-glycolic acid; PLGA) nanoparticles (NPs) to
increase the efficacy of BAR to inhibit P. gingivalis colonization in a dual species biofilm.
NPs encapsulating BAR were synthesized using double emulsion solvent evaporation
technique. We generated NPs with particle size of 207±19 nm and zeta potential of -15mV.
vi

Loading and controlled release properties of NPs were determined using a fluorescently
labeled BAR. We showed that BAR-NPs had a total payload of 14.12±0.39 µg/mL of BAR
per mg of NP, resulting in the sustained-release of BAR for up to 4 hours. Furthermore,
NPs encapsulating BAR peptide potently inhibited pre-formed P.gingivalis/ S. gordonii
biofilm. These results suggest that enhanced inhibition of P. gingivalis was be obtained
with BAR-NPs, identifying a novel therapeutic approach to effectively targeting P.
gingivalis colonization of the oral cavity.
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CHAPTER 1
INTRODUCTION
Periodontitis is defined as an inflammatory disease of the supporting tissues of the
teeth caused by specific microorganisms or groups of microorganisms, resulting in
progressive destruction of the periodontal ligament and alveolar bone with increased
probing depth formation, gingival recession, or both (1). Periodontal disease is one of the
most prevalent infectious diseases worldwide affecting between 30-50% of the global adult
population suffers from periodontal disease (2-4). In America 46% of the adults suffer from
some form of periodontal disease; corresponding to annual expenditures in excess of 14
billion dollars for treatment and prevention. An estimated 18% of the US population has
moderate periodontitis and 7% is afflicted by severe periodontitis (5). Studies have shown
that periodontal disease occurs more often in patients with systemic disease like diabetes
mellitus, AIDS, leukemia and Down’s syndrome. Periodontal diseases are also proven to
be risk factors for various systemic diseases such as infective endocarditis, cardiovascular
disease, prosthetic device infection, diabetes mellitus, respiratory diseases, rheumatoid
arthritis and adverse pregnancy outcomes (6-10).
Development of dental plaque biofilms
Periodontal disease starts with a microbial biofilm known as dental plaque. A
milder form of periodontal disease which just exhibits inflammation of the gingiva is
known as gingivitis. Maturation of biofilm within subgingival pocket together with hostsystemic and lifestyle factors cause attachment loss and lead to periodontitis.
1

Fig 1. Pathogenesis of periodontal disease. ( Hajishengallis, G. (2014). Immunomicrobial pathogenesis of
periodontitis: keystones, pathobionts, and host response. Trends in immunology, 35(1), 3-11.)

A biofilm is a structured community of microbial cells attached to a surface and is
enclosed in a polymeric matrix. In the oral cavity these surfaces can be teeth or restorative
materials. During the initial stages of biofilm formation there is adsorption of salivary
macromolecules on oral tissue surfaces which results in formation of the salivary pellicle.
Bacteria can attach to this pellicle and actively grow (12). Bacterial cells participate in a
communication process known as quorum sensing, that is an important pathway for biofilm
maturation. Quorum sensing is a cell-cell communication process that involves signaling
molecules called auto inducers (13) that allow bacteria to regulate gene expression in
2

response to changes in cell-population density. Distinct stages in biofilm formation are:
acquired pellicle formation, initial adhesion, maturation and dispersion (14).
The first step of biofilm formation is the attachment of an acquired pellicle. An
acquired pellicle is a thin protein-containing film derived from salivary glycoproteins on
the tooth surface. Interactions between various glycoproteins, other salivary components,
and the tooth surface are involved in the formation of acquired pellicle. After formation the
pellicle is ready for bacterial adhesion.
Bacterial adhesion to the pellicle is the second step of biofilm formation. Some of
the planktonic bacteria recognize binding proteins like α-amylase and proline-rich
glycoproteins/proteins and bind to the pellicle. However, in this stage the attachment is
reversible and those initially attached bacteria can detach from the pellicle easily. Early
attachments are primarily based on electrostatic or physical attachments, but later, chemical
forces become predominant (14). As the bacteria attach to the pellicle, they begin to secrete
extracellular polymeric substances which helps the bacteria stay bound together and
attached to the pellicle. Surface attachment structures including fimbriae and fibrils are the
primary means through which bacteria attach to the pellicle Actinomyces spp,
Streptococcus spp, Haemophilus spp, Capnocytophaga spp, Veillonella spp, and Neisseria
are the main pioneer bacterial genera attaching to the tooth surface (15). Early colonization
help these species occupy space and seize advantage in later competition with other
species.
Later colonizing bacteria recognize polysaccharide or protein receptors on the
pioneer bacterial cell surface and attach to them. Bacteria coaggregate, forming the typical
corn cob forms, bristle brush forms, or other forms in mature oral biofilm. Later colonizing
3

bacterial species include Fusobacterium nucleatum, Treponema spp, Tannerella
forsythensis, P. gingivalis, Aggregatibacter actinomycetemcomitans (14). The microbial
structure of a mature biofilm is significantly different from the initial biofilm, including a
populational shift that occurs during biofilm development (17). Mature biofilms typically
contain many porous layers and water channels through the biofilm, providing the bacteria
essential nutrients (18). Moreover, cell aggregation is the basis of bacterial interactions in
biofilm formation. Generally, one bacterial species can coaggregate with many other
bacterial species by cell-to-cell recognition, but this aggregation is specific because one
bacterial strain cannot aggregate with any random bacterial strains. The fundamental
mechanism promoting this aggregation is via polysaccharide or protein recognition
between bacteria (19).
In the mature biofilm, bacterial cells detach from the biofilm by single cell
detachment or a group of cells detaching. Bacterial detachment is attributed to two reasons.
The first is due to limited nutrients present at the original site, prompting the bacteria to
identify and move to a new site with more nutrients for growth. This relocation can occur
either by active dispersion or passive dispersion. Active dispersion is induced by the
bacteria themselves, while passive dispersion is caused by other bacterial species which
compete for the nutrient (20). The second reason for cell detachment is due to host defense
processes, such as the shear force of saliva, which serves to limit biofilm growth (21).

4

Fig 2. Stages of biofilm development. (Huang, R., Li, M., & Gregory, R. L. (2011). Bacterial
interactions in dental biofilm. Virulence, 2(5), 435-444.)

Role of bacteria in Periodontitis
There are two main hypotheses regarding the role of bacteria in periodontal disease.
The non-specific plaque hypothesis suggests that no one specific bacterial species is any
more significant in causing periodontal disease, relative to another. According to this
hypothesis, the accumulation of plaque results in oral diseases - not the individual bacteria
or its virulence (22). The conclusion from this hypothesis indicates that since any plaque
has the ability to cause disease, mechanical removal of plaque is an important step in
disease prevention. In light of this theory all plaque was viewed as the cause and plaque
control became the focus of periodontal therapy. The relative merits of this hypothesis is
arguable since plaque associated diseases are polymicrobial infections, but in which only
certain pathogens predominate. In contrast to this theory, the Specific plaque hypothesis
proposes that only a few specific species are actively involved in disease pathogenesis (23).
This hypothesis suggests that the primary concern is the specific bacteria that causes
disease. As such, procedures are needed to remove only those species and not all the other
species in the biofilm. However, this hypothesis could not explain the absence of pathogens
in certain disease sites or the presence of pathogens in healthy sites. A more recent
5

ecological plaque hypothesis combines the merits of both specific and non-specific plaque
hypothesis. According to ecological plaque hypothesis, disease is a result of enrichment of
some pathogens caused by ecological stress and an imbalance in the total microflora (22).
Dental biofilms are a complex community that may consist of more than 700
different bacterial species (24). Primary colonizing organisms that initiate the formation of
the biofilm consists of Gram positive organisms such as streptococci and Actinomyces spp.
Over the time there is a shift in microflora from Gram positive to Gram negative organisms
and from facultative anaerobes to strictly anaerobic species (12). Populational shifts in the
microflora can result in dysbiosis and are believed to cause periodontal disease. In subjects
with periodontal disease, red complex are directly associated with periodontal disease and
includes Tannerella forsythia, Porphyromonas gingivalis and Treponema denticola (25).

Role of Porphyromonas gingivalis in Adult Periodontitis
P. gingivalis is a non-motile, asacchrolytic, rod shaped, Gram negative anaerobic
bacterium which belongs to phylum Bacteriodetes. P. gingivalis was found in 87.75% of
sub-gingival plaque samples obtained from patients with chronic periodontitis (26). P.
gingivalis produces a multitude of virulence factors which results in destruction of
periodontal tissues by direct or indirect modulation of host inflammatory response (27).
Hajishengallis et al, 2012 identified P. gingivalis as a keystone pathogen in the
development of periodontal diseases in mice. Keystone pathogens are specific pathogens
that when present even at low abundance can cause disease by altering a normal microbiota
leading to disruption of normal host-microbe homeostasis (i.e., dysbiosis) (28).

6

Fig 3. P. gingivalis induced dysbiosis. (Hajishengallis, G., Darveau, R. P., & Curtis, M. A. (2012). The
keystone-pathogen hypothesis. Nature Reviews Microbiology, 10(10), 717-725.)

Porphyromonas gingivalis- Streptococcus gordonii interaction
The primary niche of P. gingivalis in the oral cavity is the sub-gingival pocket.
Before P. gingivalis colonizes the sub-gingival pocket it often adheres to primary
colonizers of the oral cavity like Streptococcus gordonii (29). Previous studies have shown
that adherence of P. gingivalis to oral streptococci is driven by a protein-protein interaction
that occurs between the minor fimbrial antigen (Mfa) of P. gingivalis and the streptococcal
antigen I/II (30). A region encompassing amino acids 1167 to 1250 of the SspB polypeptide
of S.gordonii antigen I/II was shown to be essential for adherence of P. gingivalis (31-33).
Subsequently, This region of SspB was compared with the corresponding region of the
Streptococcus mutans antigen I/II and demonstrated that a protein determinant comprised
amino acids 1167 to 1193, designated BAR (SspB Adherence Region), was sufficient to
promote P. gingivalis adherence (34-36). A synthetic peptide encompassing this region of
SspB functions as a potent inhibitor of P. gingivalis adherence to S. gordonii and its
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subsequent formation of biofilms in vitro (IC50= 1.3µM). BAR also inhibited P. gingivalis
virulence and colonization of the oral cavity in vivo (37). These data suggest that the initial
interaction between P. gingivalis and S. gordonii provides a potential target to prevent the
colonization of P. gingivalis in the oral cavity and one can contemplate formulating BAR
in an oral rinser or varnish to limit P. gingivalis colonization of the oral cavity. However,
a possible limitation of this approach is that BAR can only be delivered transiently.
Moreover, BAR-mediated disruption of pre-formed two-species biofilms or more complex
three-species biofilms in vitro required a higher concentration of BAR, as well as a
prolonged exposure. To address these challenges, the goal of this project was to develop
methods to deliver higher localized concentration of BAR for a prolonged duration of time.

Fig 4. Mechanism of P. gingivalis – S. gordonii co-aggregation. (Lamont, R. J., & Hajishengallis, G.
(2015). Polymicrobial synergy and dysbiosis in inflammatory disease. Trends in molecular medicine, 21(3),
172-183.)

Nanoparticles in oral diseases
The use of nanotechnology in drug delivery has gained a lot momentum in the
recent years (38). Nanoparticles are appealing vehicles to use for drug delivery because of
their characteristic features like higher surface-to-volume ratio, their ability to encapsulate
8

various hydrophobic and hydrophilic compounds. A variety of materials including dextran,
gelatin, liposomes, fullerenes, metals, silica and polymers have been used to formulate
nanoparticles. For drug delivery, it is often desirable for NPs to release the drug upon
reaching the appropriate sites and hence, biodegradable formulations can aid in this
endeavor. Poly(lactic acid ,PLA), poly(lactic-co-glycolic acid, PLGA), polycaprolactone
(PLCL) are all different biodegradable formulations that have been used for nanaoparticle
synthesis (39).
In the last few decades PLGA has been most widely accepted and studied for drug
delivery and tissue engineering applications. PLGA is a family of FDA-approved
biodegradable polymers that are highly biocompatible and have been extensively used as
controlled delivery vehicles for drugs, proteins, and various other macromolecules such as
DNA and RNA (40-42). Favorable degradation characteristics, sustained-release
properties, and surface modification has made PLGA a popular candidate for NP
formulations. In addition, mechanical strength and ability to undergo hydrolysis can be
altered by controlling parameters like molecular weight and the monomer ratio of ratio of
lactic to glycolic acid (43).
PLGA degradation is a collective process of bulk diffusion, surface diffusion, bulk
erosion and surface erosion. The initial burst of active agent during the release from
nanoparticles is dependent on the drug and polymer hydrophobicity. In the second phase,
the drug is gradually released as water hydrolyzes the polymer into oligomeric and
monomeric products (43-44).
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Fig 5. Schematic showing PLGA NP degradation. (Asmatulu, R., Fakhari, A., Wamocha, H. L., Chu, H.
Y., Chen, Y. Y., Eltabey, M. M., ... & Ho, J. C. (2009). Drug-carrying magnetic nanocomposite particles
for potential drug delivery systems. Journal of Nanotechnology, 2009.)

Fig 6. Hydrolysis of PLGA. (Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA)
as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377-1397.)

Nanofibers
In the recent years polymer nanofibers (NFs) have been used in drug delivery due
to their ease in synthesis, primarily through an electrospinning process. Various drugs,
proteins, RNA, DNA and growth factors have been incorporated into electrospun fibers
(45-47). PLGA nanofibers have been shown to increase the efficacy of various drugs.
Combined with the above mentioned properties and the ability to use it under a periodontal
pack after a surgery makes nanofibers a suitable candidate for treatment of periodontal
diseases (48).
CafA adhesin and targeting the nanoparticles
Targeting of NPs are has been widely used in drug delivery to improve the local
concentration of the drug. One method of achieving targeting is to surface modify NPs with
proteins or drugs to achieve specific targeting or binding properties. In addition to
10

specifically targeting delivery to particular niches (here in the oral cavity), surface
modification may decrease the initial release of encapsulant from the NPs, aiding in
prolonged release (49-51). Basic rationale here is to use a bacterial surface protein that can
aid in targeting these NPs to the areas in oral cavity where P. gingivalis is present. To
achieve this, we envision the use of CafA adhesin. CafA or coaggregation factor A is one
of the 14 cell surface proteins of Actinomyces oris that possess the LPXTG anchoring motif
that is recognized by sortase. CafA adhesin allows for Actinomyces/Streptococcus
coaggregation (52). Surface modification of NPs with CafA represents an approach to
target NPs or fibers to streptococcal cells, a primary initial niche of P. gingivalis in the oral
cavity.

Fig 7. Schematic representation of fimbrial structures of Actinomyces oris. (Reardon-Robinson, M. E., Wu,
C., Mishra, A., Chang, C., Bier, N., Das, A., & Ton-That, H. (2014). Pilus hijacking by a bacterial
coaggregation factor critical for oral biofilm development. Proceedings of the National Academy of
Sciences, 111(10), 3835-3840.)

BAR-modified PLGA Nanoparticles
Previous studies in our lab has shown that BAR-modified NPs potently inhibit P.
gingivalis adherence to S. gordonii. When administered simultaneously with P. gingivalis,
BAR-modified NPs exhibited an IC50 to 0.3µM which is significantly lower when
11

compared to IC50 of 1.3µM for free BAR peptide. However, in the oral cavity there is
presence of well-established and complex biofilms. Hence it is important to know if BARmodified NPs are more potent in such conditions. Parallel to this study that seek to evaluate
the efficacy of CafA modified NPs, we also intend to test the efficacy of BAR-modified
NPs in an established P. gingivalis/ S. gordonii biofilm and compare them with free BAR.

12

CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS
Research Hypothesis
We hypothesize that the delivery of BAR by sustained release PLGA (poly lacticco-glycolic acid) nanoparticles (NPs) that are targeted to specific niches in oral cavity will
increase the effectiveness of BAR against the colonization of P. gingivalis in the oral
cavity.
Specific Aims
1. Synthesize and characterize PLGA NPs that encapsulate BAR to provide
prolonged-release of the peptide.
2. Target the BAR-NPs to specific niches to the oral cavity using CafA adhesin.
3. Determine the functional efficacy of NPs on an established biofilm.

13

CHAPTER 3
METHODS
Peptide Synthesis
The BAR peptide used in this study, is shown in Table 1. The peptide is comprised
of residues 1167 to 1193 of the SspB (Antigen I/II) protein sequence of S. gordonii. The
peptide was synthesized by BioSynthesis, Inc. (Lewisville, TX) and was obtained at more
than 90% purity.

Table 1. Sequence of BAR peptide.

Peptide Peptide Sequence
BAR

NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-OH

To assess the amount of BAR encapsulated within the NPs, a peptide designated as
F-BAR was synthesized (BioSynthesis, Inc.) and 6-carboxyfluorescein was covalently
attached to the epsilon amine of the lysine residue (underlined in Table 1).
Peptide containing a covalently attached biotin at its N-terminus was also
synthesized and obtained at more than 85% purity.
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Growth of Bacterial Strains
P. gingivalis strain ATCC 33277 was grown in Trypticase soy broth media (TSBY
media) (Difco) supplemented with 0.5% (w/v) yeast extract, 1 µg/ml (final concentration)
menadione, and 5 µg/ml (final concentration) hemin. TSBY media was reduced for 24
hours under anaerobic conditions consisting of 80% N2 10% CO2 10% H2. Next, P.
gingivalis was inoculated into the medium and grown anaerobically for 48 hours at 37°C.
S. gordonii DL-1 was cultured aerobically without shaking in brain-heart infusion (BHI)
broth supplemented with 1% yeast extract for 16 hours at 37°C. A. viscosus (ATCC 43146)
was grown anaerobically in Trypticase soy broth supplemented with 5% defibrinated
sheep blood. Media was reduced for 24 hours under anaerobic conditions consisting of
80% N2 10% CO2 10% H2. A. viscosus was inoculated to the reduced media and grown
anaerobically for 24 hours at 37º C. Bacterial plasmid was extracted using Wizard®
Genomic DNA Purification Kit (Promega). E. coli strains DH5α and XL1 were grown in
Luria-Bertani broth (LB) at 37ºC overnight. The pQE-60 vector DNA was harvested from
DH5α cells using QIAprep® Spin Miniprep Kit (QIAGEN). Electrocompetent XL1 cells
were harvested from the overnight culture and stored at -80ºC in 50 µL aliquots.

Nanoparticle Synthesis
Nanoparticles encapsulating BAR or F-BAR were synthesized using a double
emulsion solvent evaporation technique. One hundred milligrams of 50:50 PLGA crystals
were dissolved in 2mL dichloromethane (DCM) overnight. The following day the
PLGA/DCM mixture was vortexed while adding 200µL of prepared mixture of BAR
(4.3µg/mg of PLGA) in TE buffer. PLGA/DCM/peptide solution was sonicated to ensure
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homogeneity. To create the second emulsion, PLGA/DCM/peptide solution was added
drop wise to 2 mL 5% PVA while vortexing. This mixture was then sonicated and added
to 50mL 0.3% PVA in DI water. The resulting solution was stirred for 3 hours on a stir
plate to allow for excess DCM evaporation. After 3 hours the solution was transferred to
tubes and centrifuged at 13,000 rpm for 10 minutes. After each centrifugation, the
supernatant was discarded and the pellets were re-suspended in 20 mL distilled water and
centrifuged. After 2 washes, the NPs were resuspended in 5mL distilled water and
transferred to a cryotube. NPs were subsequently frozen at -80˚C for 2 hours and
lyophilized for 48 hours. All NPs were stored at -20˚C. F-BAR-NPs were synthesized in
the similarly but were protected from light during the entire procedure to ensure minimal
loss of fluorescence.
Encapsulant
2nd Emulsion
Optional Ligand
Addition

Solvent
Evaporation

NPs
encapsulating
BAR

PLGA/DC
M

Fig 8. Overview of the double emulsion solvent evaporation technique for NP synthesis.

Nanofiber synthesis
In a scintillation vial, 120 mg of 50:50 PLGA was dissolved in
hexafluoroisopropanol (HFIP) overnight on a tabletop shaker. The day of synthesis BAR
(4.3µg/mg of PLGA) in 200L of TE was added to the PLGA/HFIP mixture.
PLGA/HFIP/BAR solution was then transferred into a syringe which was then placed in
the syringe driver. This emulsion was electrospun at a voltage of 20mV at a flowrate of
16

0.8mL per hour. The voltage clip was attached to the syringe needle. The fine mist of
solution was collected on a mandrel and allowed to dry for 15 minutes. After 15 minutes
the fiber was removed from the mandrel using a razor blade and placed in a petri dish in a
dessicator for 24 hours. After dessication, fibers were stored at 4˚C.

Fig 9. Schematic showing nanofiber synthesis. (Hu, X., Liu, S., Zhou, G., Huang, Y., Xie, Z., & Jing, X.
(2014). Electrospinning of polymeric nanofibers for drug delivery applications. Journal of Controlled
Release, 185, 12-21.)

BAR-Modified NPs
To synthesize BAR-modified PLGA NPs, the NP surfaces were first modified with
avidin-palmitate to attach biotinylated BAR. Avidin-palmitate was synthesized as
previously described (50). Briefly, 40 mg/4.8 mL solution of avidin was made in 2% (w/v)
sodium deoxycholate (NaDC) in PBS and warmed to 37ºC. Four milligrams per four
milliliter solution of palmitic acid-NHS (PA-NHS, Sigma) was prepared in 2% (w/v)
NaDC and sonicated until well-mixed. To the reaction vial containing avidin 3.2 mL of the
above made PA-NHS solution was added dropwise, and reacted overnight at 37ºC. The
following day, the reaction was dialyzed in 1200 mL of 0.15% (w/v) NaDC in PBS heated
to 37ºC using a 3500 molecular weight cut off (MWCO) dialysis tubing to remove free
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PA-NHS. After overnight dialysis at 37ºC, complexed avidin-palmitate was transferred to
a storage vial from the dialysis cassette and stored at 4ºC.

NPs were synthesized using an oil-in-water (o/w) single emulsion technique. 100
mg PLGA crystals were dissolved in 2 ml of DCM overnight. The next day, 2 ml of 5%
(w/v) polyvinyl alcohol (PVA) solution was mixed with 2 ml of 5mg/ml avidin-palmitate
to obtain a well-mixed solution. To create the single emulsion, 2 mL PLGA/DCM
solution was added dropwise to 4 ml PVA/avidin-palmitate while vortexing. The solution
was then sonicated to ensure homogeneity. This emulsion was then added to 50 mL of
0.3% PVA for 3 hours. to allow for the evaporation of excess DCM. The solution was
then transferred to tubes and centrifuged at 13,000 rpm at 4°C. Supernatant was discarded
and the pellets were resuspended in 9 ml distilled water. The resuspended NPs were
incubated with biotinylated BAR for 30 minutes on a benchtop at a molar ratio of 3:1
BAR: avidin. NPs were washed and lyophilized as previously mentioned in the double
emulsion technique and stored at -20C.

Physical Characterization of Nanoparticle/ Nanofiber
Nanoparticle size and morphology were determined using scanning electron
microscopy (SEM). NPs were mounted on a mounting pin with carbon tape and sputter
coated with gold under vacuum. Average particle diameter and size distribution were
determined from SEM images of at least 400 particles per batch using image analysis
software (ImageJ, National Institutes of Health). Zeta potential was measured with a
Zetasizer Nano ZS (Malvern) in diH2O to determine particle charge. Nanoparticles with a
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negative charge has less chances of aggregation. Nanofiber size, morphology and zeta
potential were determined similarly.

Functional Characterization of Nanoparticles
To determine the total payload of the NPs, 2-3 mg of NPs were dissolved in 500µL
of DCM. To this 500µL of TE buffer was added and vortexed for 1 min to extract the
peptide into the aqueous solution. The solution was then centrifuged at 13,000 rpm for 5
minutes at 4˚C and the aqueous phase is carefully removed without disturbing the organic
phase. Five hundred microliters of TE buffer was added to the remaining organic phase
and vortexed and centrifuged again to remove any remaining peptide. The amount of FBAR encapsulated was then determined by comparing fluorescence to a known standard
of F-BAR in TE. The standard was plotted by serially diluting a 1mg/mL solution of FBAR in TE. The standard and the NP samples were measured for fluorescence at 488/515
nm (excitation/emission).
To determine the sustained-release characteristics of BAR from the NPs, F-BAR
NPs were added to 1x PBS and incubated at 37˚C for 1 hour. After 1 hour the solution was
centrifuged and supernatant was removed. To the remaining NPs fresh PBS was added and
incubated until the next time point. This procedure was repeated and supernatants were
obtained at 1, 2, 4, 8, 24, 48 and 72 hour time points. The amount of F-BAR released at
each time point was measured by comparing to a known standard of F-BAR in PBS. The
standard was plotted by serially diluting a 1mg/mL solution of F-BAR in PBS. The
standard and the NP samples were measured for fluorescence at 488/515 nm.
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Functional Characterization of Nanofibers
To determine the total payload of NFs, 2-3 mgs of NFs were dissolved in DMSO
and compared to a known standard of F-BAR in DMSO. The NF samples and standards
were measured for fluorescence at 488/515 nm.
The sustained-release of BAR from NFs were determined similar to the sustained
release of NPs as mentioned above.

Dual Species Biofilm
Formation of P. gingivalis/ S. gordonii biofilms were carried out as previously
described (32). S. gordonii cells were harvested by centrifuging a 15 ml culture of S.
gordonii at 5600 rpm for 5 min. The supernatant was discarded and the cell pellet was
resuspended in 1 ml of 1x PBS. S. gordonii cells were labeled with 20 µl of 10mM
hexidium iodide for 15 min at room temperature on a rocker platform protected from light.
After incubation the labeled samples were centrifuged at 5600 rpm for 5 min, the
supernatant was discarded, and the cells were resuspended in 1ml of 1x PBS. Following
this, the optical density (O.D) was measured at 600 nm to determine cell count. For all
experiments, the optical density of S. gordonii cells was adjusted to 0.8 for uniformity of
the S. gordonii cell amounts in each well. After adjusting the optical density, 1ml of S.
gordonii cells were added to a 12 well culture plate containing a sterilized micro-coverslip
in each well. The 12 well cell culture plate was wrapped in aluminum foil to protect the
labeled cells from light and placed on a rocker platform in the anaerobic chamber at 37ºC
for 24 hours. P. gingivalis cultures used for biofilm formation were optimized using a
similar approach. 15 ml of P. gingivalis cells were centrifuged for 5 min at 5600 rpm. The
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supernatant was discarded and the cell pellet was resuspended in 1 ml of prereduced 1x
PBS. P. gingivalis cells were labeled with 15 µl of carboxyfluorescein–succinylester (4
mg/ml). Cells were incubated with the fluorescent dye for 30 min on a rocker platform
protected from light. Following incubation, cells were centrifuged at 5600 rpm for 1 min
and the supernatant was discarded. The pelleted cells were resuspended in 1ml of prereduced 1x PBS. Optical density of P. gingivalis cells were adjusted to 0.4. After removal
of unbound S. gordonii cells and washing, labeled P. gingivalis (1 ml) cells were then
added to each well of the microtiter plate. The 12 well cell culture plate was covered with
aluminum foil and incubated at 37ºC for 24 hours in an anaerobic chamber. Following
incubation, the supernatant was removed from the wells of the 12 well cell culture plate
and the treatment solutions containing free BAR or BAR-NPs in PBS were added to the
appropriate wells and incubated for 1-3 hours. Following incubation the supernatant was
removed and the wells were washed with pre-reduced 1x PBS to remove non-adherent
bacterial cells. The cells were subsequently fixed with 4% (w/v) paraformaldehyde, excess
paraformaldehyde was removed, and the cells were washed with pre-reduced 1x PBS. The
coverslip was then mounted on to a glass slide using Prolong Gold anti-fade reagent and
viewed using confocal laser scanning microscopy.

Confocal Microscopy
P. gingivalis- S. gordonii biofilms were visualized using a Leica TCS SP8 confocal
microscope (Leica Microsystems). The slides were viewed using an argon laser for
visualization of FITC-labeled P. gingivalis and the HeNe-G laser to visualize hexidium
iodide- labeled streptococci. P. gingivalis binding was determined from randomly chosen
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frames using LAS X software. Z-stack images of the biofilms were obtained using a z-step
size of 0.7 µm.

Image Analysis
The images obtained from confocal microscopy were processed and reconstructed
into 3D images using the Volocity software. Images were imported into Volocity as .tiff
files. Uniform filters were used to remove noise from the images and were further analyzed
to quantify the extent of P. gingivalis binding. The image brightness and contrast was
adjusted equally for all frames, and a snapshot of the image was captured. Next, the ratio
of green to red fluorescence was determined. Each sample was analyzed in triplicate and 3
independent frames were measured for each well. Statistical significance between samples
was determined using ANOVA. The variation was considered statistically significant when
P<0.05.

Recombinant CafA expression in E. coli
Forward and reverse primers used for amplification of cafA gene are shown in
Table 2.
Table 2. Primers used for amplification of cafA gene.

Forward Primer

5’- CAC CAT GGT GAT CGA CTG GAT CGA CTG -3’

Reverse Primer

5’- CAG ATC TGA TCT TGC CCA GCG C -3’

The cafA gene of A. viscosus (lacking the LPXTG anchoring motif) was amplified using
the primers shown in Table 2 by PCR using Radiant™ HiFi Ultra Polymerase. PCR
protocol and cycling conditions used were as described in Table 3.
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Table 3.1. PCR protocol used for amplification of the cafA gene.

Component
RadiantTM 5x HiFi Ultra Reaction Buffer
Forward Primer (10μM)
Reverse Primer (10μM)
Template DNA
RadiantTM HiFi Ultra Polymerase (2u/μl)
PCR-grade water

50μl
Reaction
10 μl
2.0 μl
2.0 μl
1.0 μl
0.5 μl
34.5 μl

Final
Concentration/Notes
1X
400 nM
400 nM
387ng

Table 3.2. PCR cycling conditions used for amplification of the cafA gene.

1
30

Cycles

Temperature & Time
95°C 1 minute
95°C 15 seconds
68°C 15 seconds
72°C 30 seconds per Kb

Notes
Initial Denaturation
Denaturation
Annealing
Extension 1min 30s

PCR products were then concentrated using DNA Clean & Concentrator™-5
(Zymo Research). The insert and vector DNA (pQE-60; Fig 10) were then digested using
restriction endonucleases (NcoI and BglII) to create sticky ends for ligation. The digested
insert and vector DNA were then ligated using T4 DNA Ligase (New England BioLabs
Inc.).

23

Fig 10. Vector map for pQE-60.

Vector containing the desired insert was then transformed into XL1
electrocompetent cells by electroporation. The cells were allowed to grow in SOC medium
containing no antibiotics at 37˚C for 45 min. Following this the cells were streaked on a
LB agar plate containing tetracycline and ampicillin (1µL/mL) and allowed to grow
overnight at 37˚C (Fig 11). Individual colonies were selected and passaged in LB broth
containing tetracycline and ampicillin (1µL/mL).
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Fig 11. Schematic overview of bacterial transformation. (www.addgene.org)
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CHAPTER 4
RESULTS
BAR requires prolonged exposure to inhibit established two species biofilm
Previous studies have shown that BAR requires prolonged exposure (>60 mins) to
inhibit established three-species biofilm (29). To determine the time required by BAR to
inhibit an established two-species biofilm, 3µM of free BAR was used to treat an
established P. gingivalils/ S. gordonii biofilm for 1, 2 and 3 hours. P. gingivalis and S.
gordonii microcolonies were then visualized by confocal scanning microscopy, and the
number of microcolonies that formed per microscope ﬁeld-of-view were recorded for each
time point. As summarized in Table 4, treating the biofilm for 3 hours with BAR resulted
in ~55% inhibition of the P. gingivalis microcolonies. In contrast, treatment for 1 and 2
hours showed no significant inhibition of P. gingivalis (P> 0.05). Figure 12 shows the ratio
of P. gingivalis/ S.gondonii microcolonies were statistically significant between the control
and treatment groups at 3 hour time point. This lower ratio means more inhibition of P.
gingivalis colonies. This experiment provides preliminary data that supports the hypothesis
that sustained release NPs can increase BAR effectiveness against established biofilms by
reducing the amount of P. gingivalis bound to S. gordonii.
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Time in hours Ratio between P. gingivalis and S. gordonii
Control (Mean ± SD) Treated (Mean ± SD)
1

0.23±0.009

0.21±0.019

2

0.33±0.013

0.31±0.013

3

0.33±0.006

0.15±0.011

Table 4. Effect of prolonged exposure of BAR on the ratio between P. gingivalis and S. gordonii.

Fig. 12. Ratio of P. gingivalis and S. gordonii microcolonies treated with 3µM of BAR for 1, 2 and 3 hours.
*, the ratio was statistically significant (P< 0.05)

Nanoparticle synthesis and characterization.
Analysis of SEM images (Fig. 13) revealed that the average size of NPs are
207±19nm and exhibit the expected spherical morphology. Zeta potential values for NPs
were -15mV.
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Fig 13. SEM image of BAR NPs

Loading experiments
In this experiment the amount of BAR encapsulated within the NPs was
determined. Total fluorescence emitted by the NPs were converted to an amount of BAR
by comparing the fluorescence to a known standard of F-BAR in TE. Loading experiments
showed a total payload of 14.12±0.39 µg of BAR per mg of NP. This corresponded to an
encapsulation efficiency of 33%.

Dose dependent loading of nanoparticles
To determine the dose dependent loading and encapsulation efficiency, NPs were
synthesized using and initial concentration of 10µg, 21µg and 43µg per mg of PLGA.
Fig 14 shows the total payload and the encapsulation efficiency for each batch of NPs.
There is no significant difference in the percent encapsulation efficiency (P>0.05), but
there is a dose-dependent increase in the total amount of BAR encapsulated. This suggests
that NPs can be synthesized with varying concentrations of BAR to achieve optimal
loading.
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Fig 14.1. Dose dependent encapsulation of BAR.
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Fig 14.2. Dose dependent encapsulation efficiency of BAR.
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Nanofiber characterization

Fig 15. SEM image showing BAR NFs.

Similar to NPs, we validated the diameter and morphology of BAR NFs using SEM. Figure
15 depicts uniformly sized, well- delineated fibers with average size of 917±256 nm. To
determine the total pay load aliquots of NFs were dissolved in DMSO and the amount of
fluorescence emitted was converted to an amount of BAR by comparing to known
standards of F-BAR in DMSO. Loading experiment to determine the total amount of BAR
encapsulated in the fibers showed an encapsulation of 46.8± 0.63 µg of BAR per mg of
NF, corresponding to an encapsulation efficiency of 92%.

BAR nanoparticles provide sustained release of BAR
For this experiment aliquots of BAR were incubated in PBS at 37 ºC. Supernatant
from various time points were used to measure the fluorescence. Triplicate fluorescence
readings at each time points were compared to a known standard of F-BAR in PBS. Fig
16.1 shows the total concentration of BAR released at each time point over a 24 hour
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period. Fig 16.2 shows the percentage of encapsulated BAR released at each time point
over a 24 hour period.

Cumulative release of BAR per mg
of NP (µg/mL)
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Fig 16.1. Total amount of BAR released per mg NPs over a 24 hour period.
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Fig 16.2. Percent of encapsulated BAR released per mg NPs over a 24 hour period.

31

Nanofibers provide sustained release of BAR in lower concentrations than NPs
To determine the sustained-release of BAR, NFs were incubated with in PBS at 37ºC.
Similar to NP sustained-release experiments, the supernatant from each release time point
was assessed to determine the amount of BAR released. The amount of F-BAR released at
each time points was compared to a known standard of F-BAR in PBS. Fig. 17.1 and 17.2
show the total amount of BAR and the percent encapsulate BAR, released at each time
point over a 24 hour period, respectively. Although NFs showed a higher encapsulation per
mg of fiber (46.8± 0.63 µg/mg), relative to NP loading (14.12±0.39 µg/mg), less BAR was
released over a 24 hour time period (1.23 µg/mg vs. 10.7 µg/mg)
Cumulative release of BAR per mg of
fiber (µg/mL)
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Fig 17.1. Total amount of BAR released per mg fiber over a 24 hour period.
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Fig 17.2. Percent of encapsulated BAR released per mg fiber over a 24 hour period.

Sustained release BAR-NPs inhibit established P. gingivalis/ S. gordonii biofilms.
To determine if BAR-encapsulated NPs inhibit P. gingivalis on an established P.
gingivalis/ S. gordonii biofilm, P. gingivalis biofilms were formed on immobilized
streptococci. Various molar concentrations of BAR-NPs in PBS were used to treat the
established biofilm for 1 hour. Sufficient amounts of NPs to deliver BAR peptide
concentrations ranging from 0.3 to 3 µM were tested and compared with 3 µM of free
soluble BAR. Only one concentration of soluble BAR (3 µM) was used because the
previous experiment showed 3µM of soluble BAR having no significant effect on
established biofilms when treated for 1 hour. P. gingivalis/ S. gordonii microcolonies were
visualized using confocal scanning microscopy and the ratio of green (P. gingivalis) and
red (S. gordonii) fluorescence was quantified using Volocity image analysis software. For
control reactions, the biofilms were treated with blank NPs for the same amount of time.
The images of biofilms treated with BAR-NPs, soluble BAR or buffer alone are shown in
Fig.18. As summarized in Table 5, BAR-NPs exhibited dose dependent inhibition of the
33

dual species biofilm with the ratio of green to red fluorescence being significantly reduced
(P<0.05) at 1.7 M and 3 µM. As expected 3 µM soluble BAR had no effect on the ratio
of green and red fluorescence. The striking result was that while soluble BAR required a
prolonged exposure of 3 hours, BAR-NPs showed a significant reduction in the ratio of
green and red fluorescence in just 1 hour.

Control

Free BAR 3µM

BAR-NP 0.3 µM
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BAR-NP 1.7 µM

BAR-NP 3 µM
Fig. 18. Confocal microscopy images showing untreated, free BAR treated and BAR-encapsulated NP
treated biofilms.

Table 5. Effect of free BAR, sustained release-NPs and BAR-modified NPs on the ratio between
P.gingivalis and S. gordonii. Percentage inhibition in relation to the control is shown in ( ).

0.3 µM

1.7 µM

3 µM

Control

0.28±0.01

Free BAR peptide

0.26±0.02
(5%)

Sustained-release

0.25±0.01

0.22±0.01

0.13±0.00

BAR-NPs

(6%)

(17%)

(51%)

BAR-modified NPs

0.27±0.01

0.19±0.01

0.11±0.01

(4%)

(27%)

(59%)
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BAR-modified NPs inhibit established P. gingivalis/ S. gordonii biofilms.
Previously it was shown that BAR modified NPs competitively bind to P. gingivalis
and prevent its initial colonization of the oral cavity (49). However in the oral cavity more
complex and established biofilms are present. To determine if BAR modified NPs inhibit
P. gingivalis on an established P. gingivalis/ S. gordonii biofilm, P. gingivalis biofilms
were formed on immobilized streptococci. Various molar concentrations of BAR-modified
NPs in PBS were used to treat the established biofilm for 1 hour. Sufficient amounts of
NPs to deliver BAR peptide concentrations ranging from 0.3 to 3 µM were tested. P.
gingivalis/ S. gordonii microcolonies were visualized using confocal scanning microscopy
and the ratio of green (P. gingivalis) and red (S. gordonii) fluorescence was quantified
using Volocity image analysis software. These results were then compared to control
biofilms and biofilms treated with 3 µM of soluble BAR. The images of biofilms treated
with BAR modified NPs are shown in Fig.19. and quantified in Table 5, BAR-modified
NPs exhibited dose dependent inhibition of the dual species biofilm with the ratio of green
to red fluorescence being significantly reduced (P<0.05) at 1.7 µM and 3 µM. Yet again
the striking result was that while soluble BAR required a prolonged exposure of 3 hours,
BAR-NPs showed a significant reduction in the ratio of green and red fluorescence in just
1 hour.

BAR modified NP 0.3 µM
36

BAR modified NP 1.7 µM

BAR modified NP 3 µM
Fig. 19. Confocal microscopy images showing untreated, free BAR treated and BAR-modified NP treated
biofilms.
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Fig. 20. Ratio of P. gingivalis and S. gordonii microcolonies treated with free BAR, Sustained released
(SR) NPs, BAR modified (BM) NPs. *, the ratio was statistically significant relative to control and free
BAR treated biofilms. (P< 0.05)
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Expression of CafA adhesion for targeting nanoparticles
Insert gene was amplified using PCR. Gel electrophoresis of the PCR products
showed an acceptable size of approximately 2500 base pairs (Fig 21)

Fig 21. Gel electrophoresis showing PCR products amplifying cafA gene.

This insert DNA was the digested and ligated with PQE60 vector and successfully
electroporated into XL1 competent cells. Plasmid from recombinant E. coli was sent to
sequencing. A BLAST® search of the sequencing results showed that the recombinant E.
coli was coding for collagen binding protein and not CafA.
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CHAPTER 5
DISCUSSION
One of the most common infectious diseases of the oral cavity, periodontitis, results
in tooth loss and significantly affects patient quality of life. Periodontitis is considered to
be a public health problem and a significant economic investment is made on treatment
and prevention. The multifactorial disease etiology and, treatments based on limiting the
disease progression combined with the decreased bioavailability of antibiotics in the
diseased site have all resulted in difficulty managing periodontal diseases effectively.
Periodontitis is an inflammatory disease most often associated with the overgrowth
of P. gingivalis. The primary niche for P. gingivalis is in the anaerobic sub gingival pocket
of the oral cavity; however the initial colonization occurs when P. gingivalis interacts with
oral commensals. One such interaction important for P. gingivalis colonization is the
species specific interaction with S. gordonii. Previous studies have identified that this
interaction is mediated by Mfa1 of P. gingivalis and SspB polypeptide of S. gordonii. This
initial interspecies interaction represents a potential target for limiting P. gingivalis
colonization and prevent periodontal diseases. A synthetic analog of the SspB polypeptide
designated BAR was identified. BAR was successful in limiting P. gingivalis colonization
both in vitro and in vivo. While BAR is effective in limiting the initial colonization of P.
gingivalis, it was shown to be less effective against well-established and complex biofilms.
Our preliminary studies revealed that a prolonged exposure of BAR can significantly
inhibit P. gingivalis in an established two species P. gingivalis/ S. gordonii biofilm. In this
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study, we hypothesized that targeted PLGA nanoparticles encapsulating BAR peptide may
increase the potency of BAR by providing a higher localized concentration of BAR for a
prolonged duration of time.
We successfully and reproducibly synthesized NPs that encapsulate BAR. BAR
encapsulated NPs resulted in a gradual release of BAR. This suggest a therapeutic approach
to release BAR to inhibit P. gingivalis. NPs continued to release BAR up to 24 hours but
the amounts were significantly low. We envision that surface modification of these NPs
will help not just to target them but also prolong the release for up to 24 hours. Various
polymer blends like PLA, PLCL or different lactide to glycolide ratio of PLGA can be used
for synthesis of NPs to prolong the release beyond 24 hours. Our goal is to achieve an
optimum concentration of BAR for 24 hours since our ultimate goal is to use these NPs
therapeutically.
In addition to prolonging BAR delivery, another approach is to localize NPs in the
oral cavity for longer duration. To achieve this and maximize NP efficacy, it is important
that the NPs are present in areas of the oral cavity where P. gingivalis is present. To target
NPs to these niches, a surface adhesin CafA found on A. oris can be used. CafA is a surface
protein found on A. oris which helps it to coaggregate with streptococci. CafA reacts with
a surface carbohydrate that is expressed by many of the streptococcus species that P.
gingivalis interacts with.
One strategy is to surface modify NPs with CafA to target them to region where
oral streptococci and P. gingivalis are present in the oral cavity. Since CafA is not
commercially available, the gene that encodes for CafA was amplified and expressed in E.
coli. The resulting recombinant E. coli was unsuccessful in expressing CafA. The potential
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reason for the failure in exression of CafA was a mis-anotation of cafA gene in oralgen.
Further experiments are underway to design new primers to try create a new recombinant
E. coli to express CafA. If there is difficulty in expressing CafA other proteins like Fab
fragments from existing anti-SspB antibodies can be used to surface modifiy NPs.
Nanofibers are polymeric fibers synthesized by electrospinning of the polymer.
Electrospinning is rather inexpensive and user friendly process used to fabricate
nanofibers. Fibers are traditionally used in gingival sulcus to provide a better localized
concentration of drugs. Different fibers used in local periodontal therapy are tetracycline
fiber, doxycycline polymer, chlorhexidine chip, etc. The ability to use BAR fibers within
the sulcus which is the primary niche of P. gingivalis will help in improved local
concentration of BAR and better inhibition of P. gingivalis.
Electrospun nanofibers encapsulating BAR had a higher payload but the release
kinetics showed poor release in the first 24 hours. While this suggests that NFs are capable
of releasing BAR over a period of weeks or months, they were unable to deliver at least
the IC50 concentration of BAR. The reason why NFs were unable to release higher
concentration of BAR is not known at this time. Various polymers can be tried to optimize
the release kinetics of the NFs. The ease of synthesis and the ability to use in the
subgingival pocket makes NFs a very good candidate for delivery of BAR.
Our results show that a 1 hour treatment using a molar equivalent of BAR-NP
resulted in significantly higher inhibition of P. gingivalis in an established biofilm than a
3 hour treatment using free BAR. We believe that the greater efficacy of BAR-NPs will be
helpful in developing NPs in therapeutic formulations such as a toothpaste, mouth rinse or
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chewing gum. Surface modification to bind to other oral bacteria might further help in
longer bioavailability and higher local concentration of BAR.
BAR-modified NPs have also shown to inhibit P. gingivalis in an established
biofilm. Together these experiments suggest that NPs can deliver higher localized
concentration of BAR sufficient to inhibit P. gingivalis in an established two species
biofilm. Our results suggest that use of nanotechnology is a novel approach which can
successfully be used to prevent oral diseases by limiting pathogen colonization of the oral
cavity. We also understand that periodontal diseases have a multispecies etiology. The
versatility of nanotechnology to use multiple proteins in the same nanoparticle formulation
will allow to target other species of bacteria to limit periodontitis.
Future studies will focus on expression of CafA adhesin which will then be
biotinylated and conjugated to avidin-NPs as done in BAR modification of NPs. If
necessary, the level of surface associated CafA will be adjusted to increase or decrease the
retention on streptococci. Once appropriate retention is achieved, the controlled release
profile will be assessed to determine if surface modification has affected the release
kinetics. Additional studies will focus on optimizing the total payload by various ratios of
polymer formulations used for nanoparticle synthesis. Further experiments will test the
ability of targeted sustained release BAR-NPs to reduce P. gingivalis colonization both in
vitro and in vivo. Additionally, BAR-NPs can be tested on more complex three species
biofilms. Following this, experiments will be done to examine the toxicity of targeted
sustained release NPs against human gingival cells and methods to formulate NP
preparations will be studied. We are also working on more economical alternatives like
peptidomimetics of BAR. If successful in identifying a peptidomimetic for BAR the same
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nanotechnology can be used as a delivery vehicle for these peptidomimetics to inhibit P.
gingivalis. Our long term goal is to develop these NPs to be tested for efficacy in humans
in a clinical trial. Studies will be focused to test the toxicity of NPs against human oral
gingival and innate immune cells. Once NPs are shown to be non-toxic they will be tested
for their efficacy to prevent P. gingivalis colonization and re-colonization after treatment.
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